Búsqueda | Portal de Búsqueda de la BVS

1.

Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion.

Youssef, Amer; Clark, Justin R; Marcovina, Santica M; Boffa, Michael B; Koschinsky, Marlys L.

Arterioscler Thromb Vasc Biol ; 42(3): 289-304, 2022 03.

Artículo en Inglés | MEDLINE | ID: mdl-35045727

2.

Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme.

Garabon, Justin J W; Boffa, Michael B.

J Thromb Thrombolysis ; 56(2): 283-290, 2023 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-37310666

3.

Understanding the ins and outs of lipoprotein (a) metabolism.

Boffa, Michael B; Koschinsky, Marlys L.

Curr Opin Lipidol ; 33(3): 185-192, 2022 06 01.

Artículo en Inglés | MEDLINE | ID: mdl-35695615

4.

Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a).

Clark, Justin R; Gemin, Matthew; Youssef, Amer; Marcovina, Santica M; Prat, Annik; Seidah, Nabil G; Hegele, Robert A; Boffa, Michael B; Koschinsky, Marlys L.

J Lipid Res ; 63(6): 100216, 2022 06.

Artículo en Inglés | MEDLINE | ID: mdl-35469919

5.

Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a).

Marcovina, Santica M; Clouet-Foraison, Noémie; Koschinsky, Marlys L; Lowenthal, Mark S; Orquillas, Allen; Boffa, Michael B; Hoofnagle, Andrew N; Vaisar, Tomás.

Clin Chem ; 67(3): 490-499, 2021 03 01.

Artículo en Inglés | MEDLINE | ID: mdl-33517366

6.

Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups.

Paré, Guillaume; Çaku, Artuela; McQueen, Matthew; Anand, Sonia S; Enas, Enas; Clarke, Robert; Boffa, Michael B; Koschinsky, Marlys; Wang, Xingyu; Yusuf, Salim.

Circulation ; 139(12): 1472-1482, 2019 03 19.

Artículo en Inglés | MEDLINE | ID: mdl-30667276

7.

Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?

Boffa, Michael B; Koschinsky, Marlys L.

Curr Opin Lipidol ; 30(6): 428-437, 2019 12.

Artículo en Inglés | MEDLINE | ID: mdl-31577611

8.

Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

Boffa, Michael B; Marar, Tanya T; Yeang, Calvin; Viney, Nicholas J; Xia, Shuting; Witztum, Joseph L; Koschinsky, Marlys L; Tsimikas, Sotirios.

J Lipid Res ; 60(12): 2082-2089, 2019 12.

Artículo en Inglés | MEDLINE | ID: mdl-31551368

9.

The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?

Boffa, Michael B; Koschinsky, Marlys L.

Curr Opin Lipidol ; 29(3): 259-267, 2018 06.

Artículo en Inglés | MEDLINE | ID: mdl-29528858

10.

Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.

Scipione, Corey A; Koschinsky, Marlys L; Boffa, Michael B.

Crit Rev Clin Lab Sci ; 55(1): 33-54, 2018 01.

Artículo en Inglés | MEDLINE | ID: mdl-29262744

11.

Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach.

Paquet, Maryse; Cerasuolo, Joshua O; Thorburn, Victoria; Fridman, Sebastian; Alsubaie, Rasha; Lopes, Renato D; Cipriano, Lauren E; Salamone, Paula; Melling, C W James; Khan, Ali R; Sedeño, Lucas; Fang, Jiming; Drangova, Maria; Montero-Odasso, Manuel; Mandzia, Jennifer; Khaw, Alexander V; Racosta, Juan M; Paturel, Justin; Samoilov, Lucy; Stirling, Devin; Balint, Brittany; Jaremek, Victoria; Koschinsky, Marlys L; Boffa, Michael B; Summers, Kelly; Ibañez, Agustín; Mrkobrada, Marko; Saposnik, Gustavo; Kimpinski, Kurt; Whitehead, Shawn N; Sposato, Luciano A.

J Stroke Cerebrovasc Dis ; 27(3): 606-619, 2018 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-29141778

12.

Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Boffa, Michael B; Koschinsky, Marlys L.

J Lipid Res ; 57(5): 745-57, 2016 05.

Artículo en Inglés | MEDLINE | ID: mdl-26647358

13.

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.

Romagnuolo, Rocco; Scipione, Corey A; Boffa, Michael B; Marcovina, Santica M; Seidah, Nabil G; Koschinsky, Marlys L.

J Biol Chem ; 290(18): 11649-62, 2015 May 01.

Artículo en Inglés | MEDLINE | ID: mdl-25778403

14.

Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.

Bazzi, Zainab A; Lanoue, Danielle; El-Youssef, Mouhanned; Romagnuolo, Rocco; Tubman, Janice; Cavallo-Medved, Dora; Porter, Lisa A; Boffa, Michael B.

BMC Cancer ; 16: 328, 2016 05 24.

Artículo en Inglés | MEDLINE | ID: mdl-27221823

15.

Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.

Boffa, Michael B.

Curr Atheroscler Rep ; 18(12): 69, 2016 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-27761705

16.

Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).

Scipione, Corey A; Sayegh, Sera E; Romagnuolo, Rocco; Tsimikas, Sotirios; Marcovina, Santica M; Boffa, Michael B; Koschinsky, Marlys L.

J Lipid Res ; 56(12): 2273-85, 2015 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-26474593

17.

Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).

Romagnuolo, Rocco; Marcovina, Santica M; Boffa, Michael B; Koschinsky, Marlys L.

J Lipid Res ; 55(4): 625-34, 2014 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-24478033

18.

Lipoprotein(a): lodestar for future clinical trials.

Watts, Gerald F; Boffa, Michael B.

Lancet ; 392(10155): 1281-1282, 2018 10 13.

Artículo en Inglés | MEDLINE | ID: mdl-30293767

19.

Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13.

Madarati, Hasam; DeYoung, Veronica; Singh, Kanwal; Sparring, Taylor; Kwong, Andrew C; Fredenburgh, James C; Teney, Cherie; Koschinsky, Marlys L; Boffa, Michael B; Weitz, Jeffrey I; Kretz, Colin A.

Sci Rep ; 14(1): 9073, 2024 04 20.

Artículo en Inglés | MEDLINE | ID: mdl-38643218

20.

A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.

Koschinsky, Marlys L; Bajaj, Archna; Boffa, Michael B; Dixon, Dave L; Ferdinand, Keith C; Gidding, Samuel S; Gill, Edward A; Jacobson, Terry A; Michos, Erin D; Safarova, Maya S; Soffer, Daniel E; Taub, Pam R; Wilkinson, Michael J; Wilson, Don P; Ballantyne, Christie M.

J Clin Lipidol ; 2024 Mar 29.

Artículo en Inglés | MEDLINE | ID: mdl-38565461

Portal de Búsqueda de la BVS

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion.

Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme.

Understanding the ins and outs of lipoprotein (a) metabolism.

Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a).

Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a).

Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups.

Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?

Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis.

The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?

Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.

Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach.

Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.

Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.

Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.

Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).

Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a).

Lipoprotein(a): lodestar for future clinical trials.

Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13.

A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.